[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-apnea-obstructive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-apnea-obstructive":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,44,70,97,128,152,181,208,230,256,290,314,337,374,394,413,439,463,486,507,530,554,579,614,637],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100109911","phase-2-drug-induced-sleep-endoscopy-for-upper-airway-evaluation-in-obstructive-sleep-apnea-100109911",false,"NCT00695214","Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Adult patients with OSA considering surgical treatment\n\nExclusion Criteria:\n\n* Minors\n* Pregnant women\n* Patients unable to provide informed consent in English themselves\n* Prisoners\n* Allergy to propofol, soybean oil, egg lecithin or glycerol\n* Other contraindication to use of propofol (decision of anesthesiologist or otolaryngologist.)","ALL","18 Years",{"count":19,"type":20},800,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Prospective, interventional cohort study of drug-induced sleep endoscopy (DISE) to evaluate the upper airway in a cohort of obstructive sleep apnea (OSA) surgical patients. This study has investigated the reliability of this technique, demonstrating moderate-substantial interrater and test-retest reliability. This research has also compared DISE findings to those of the lateral cephalogram X-ray and examined DISE findings in individuals who have not responded to previous sleep apnea surgery. These papers have been published and available through PubMed. Additional research is ongoing, with examination of DISE findings, comparison to other evaluation techniques, and the association between DISE findings and surgical outcomes.",[26],"Sleep Apnea, Obstructive",[28,29,30],"Obstructive Sleep Apnea","Propofol","Sleep Endoscopy","RECRUITING","2026-06-29",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2004-02",{"date":39,"type":20},"2035-06",{"name":41,"class":42},"University of California, Los Angeles","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100621314","phase-3-a-study-of-eloralintide-ly3841136-in-participants-with-obstructive-sleep-apnea-and-obesity-or-overweight-100621314","NCT07369011","A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight","A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight","ENLIGHTEN-3","Inclusion Criteria:\n\n* Confirmed history of moderate-to-severe OSA\n* Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening\n* Have a BMI ≥27 kg\u002Fm2 at screening\n* Have a stable body weight (\\\u003C5% body weight change) for 90 days prior to screening\n* Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight\n\nFor YSA1 Participants:\n\n* Are unable or unwilling to use PAP therapy\n\nFor YSA2 Participants:\n\n* Have been on PAP therapy for at least three consecutive months prior to screening and plan to continue PAP therapy during the study\n\nExclusion Criteria:\n\n* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \\>1 year before screening)\n* Have a prior or planned endoscopic procedure and\u002For device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)\n* Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery that still may affect breathing at time of screening\n* Have type 1 diabetes, type 2 diabetes, or any other type of diabetes\n* Have had within 90 days prior to screening:\n\n  * acute myocardial infarction\n  * cerebrovascular accident (stroke)\n  * coronary artery revascularization\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure\n* Have taken medications or alternative remedies intended for weight loss within 90 days of screening",{"count":19,"type":20},[54],"PHASE3","The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.\n\nParticipants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.",[26,57,58],"Obesity","Overweight","2026-06-19",{"date":61,"type":35},"2026-06-23",{"date":63,"type":35},"2026-02-10",{"date":65,"type":20},"2028-04",{"name":67,"class":68},"Eli Lilly and Company","INDUSTRY",129,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100351774","phase-1-benefits-of-oxytocin-in-obstructive-sleep-apnea-osa-patients-using-continuous-positive-airway-pressure-cpap-machine-100351774","NCT03860233","Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine","Benefits of Oxytocin in OSA Patients Using CPAP","Inclusion Criteria:\n\n* Men or women 18 years of age or older.\n\nExclusion Criteria:\n\n* subjects not willing to or otherwise unable to use CPAP for treatment of OSA.\n* Presence of other sleep disorders\n* Pregnant or breastfeeding women\n* Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study\n* Prisoners or subjects who are involuntarily incarcerated\n* Subjects who are compulsorily detain or treatment of either a psychiatric or physical (i.e. infectious disease) illness\n* Patients unable to give consent because of a language barrier, or other reason.",{"count":78,"type":20},40,[80],"PHASE1","This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea.\n\nThis study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.",[83,26],"Sleep Apnea",[85,86,87],"Continuous Positive Airway Pressure","CPAP","Oxytocin","2026-04-28",{"date":90,"type":35},"2026-05-04",{"date":92,"type":35},"2019-03-04",{"date":94,"type":20},"2026-12-31",{"name":96,"class":42},"Vivek Jain",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":43},"100468666","home-apnea-testing-in-children-trial-100468666","NCT05382754","Home Apnea Testing in CHildren Trial","Home Sleep Apnea Testing Compared to In-lab Polysomnography for the Evaluation of Obstructive Sleep Apnea in Children","HATCH","Inclusion Criteria:\n\n* Male and female children age 5-12 years old inclusive\n* Referred for diagnostic PSG at the Children's Hospital of Philadelphia (CHOP) Sleep Laboratory for evaluation of OSA as part of clinical care\n* Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria:\n\n* Children without Down syndrome who have had a PSG within 3 years of enrollment\n* Children with Down syndrome who have had a PSG within 1 year of enrollment.\n* Children with a history of hypoventilation or hypoxemia or who require supplemental oxygen or positive airway pressure during sleep\n* Children with a tracheostomy or tracheocutaneous fistula\n* Children who live in a facility without their parent","5 Years","12 Years",{"count":108,"type":20},317,[110],"NA","This clinical trial will compare home sleep apnea testing with the gold standard in-lab polysomnography in terms of 1) accuracy, 2) therapeutic decision-making, and 3) parent\u002Fchild acceptability in children referred for evaluation of obstructive sleep apnea.",[26,113,114,115],"Sleep Disorder","Sleep Apnea Syndromes","Sleep Disturbance",[117,118],"obstructive sleep apnea","home sleep apnea testing","2026-04-16",{"date":121,"type":35},"2026-04-21",{"date":123,"type":35},"2023-03-29",{"date":125,"type":20},"2027-07",{"name":127,"class":42},"Children's Hospital of Philadelphia",{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":43},"100511476","impact-of-the-mandibular-advancement-device-on-sleep-apnea-during-cpap-withdrawal-100511476","NCT05939934","Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal","Impact of the Mandibular Advancement Device on Sleep Apnea Syndrome During Discontinuation of Treatment With Continuous Positive Airway Pressure: Randomized Controlled Trial","ORTAP","Inclusion Criteria:\n\n* Patient accepting MAD treatment\n* Patient with an apnea-hypopnea index (AHI) greater than 15 events per hour on the initial recording\n* Patient with excessive daytime sleepiness during initial treatment (ESE\\>10)\n* Patient treated for more than 12 months by CPAP with average compliance greater than 5 hours per night\n\nExclusion Criteria:\n\n* Initial severe daytime sleepiness characterized\n* OSAS with ≥ 5 central apneas per hour of sleep at baseline recording\n* Previously diagnosed severe cardiac and\u002For respiratory pathology:\n* Body mass index ≥ 35 kg\u002Fm2\n* Known contraindication to OAM treatment","75 Years",{"count":78,"type":20},[110],"Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences. Continuous positive pressure (CPAP), the main treatment for OSAHS, is effective on the majority of symptoms but restrictive, which can promote non-compliance. Treatment interruptions are often observed in connection with intercurrent events such as nasal obstructions or even when patients are on the move. However, randomized trials have shown that stopping treatment, even for a short time, leads to a recurrence of symptoms and significant CV disturbances (increase in blood pressure, endothelial dysfunction, cardiac repolarization disorders). It seems important to consider strategies that promote therapeutic continuity. The mandibular advancement device (MAD) is an interesting tool in this regard. MAD is as effective as CPAP on symptoms and CV data. The investigators want to assess its effectiveness as a complementary treatment during treatment discontinuation on the main consequences of OSAHS.",[26,141],"Endothelial Dysfunction","2026-03-31",{"date":144,"type":35},"2026-04-06",{"date":146,"type":35},"2024-03-05",{"date":148,"type":20},"2026-11",{"name":150,"class":151},"University Hospital, Angers","OTHER_GOV",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":43},"100629025","high-intensity-progressive-inspiratory-muscle-training-in-class-iii-obesity-and-obstructive-sleep-apnea-100629025","NCT07469280","High-Intensity Progressive Inspiratory Muscle Training in Class III Obesity and Obstructive Sleep Apnea","High-Intensity Progressive Inspiratory Muscle Training in Class III Obesity and Obstructive Sleep Apnea: Study Protocol for a Prospective Nonconcurrent Multiple-Baseline Single-Case Experimental Design With Stability-Based Phase Transition","Inclusion Criteria: -Adults (≥18 years).\n\n* Of both genders.\n* Class III obesity (BMI \\> 40 kg\u002Fm²).\n* Diagnosis of OSA.\n* Without neurological conditions that would prevent them from responding to the study assessments.\n\nExclusion Criteria:\n\n* Systemic diseases (pulmonary, cardiac or renal).\n* Are using medications that may affect muscle performance.\n* Are currently using CPAP therapy.\n* Conditions that could compromise adherence to the study protocol.",{"count":160,"type":20},10,[110],"The purpose of this study is to evaluate the feasibility and effects of a 12-week high-intensity progressive Inspiratory Muscle Training (IMT) program in individuals with Class III obesity (BMI ≥ 40 kg\u002Fm²) and obstructive sleep apnea (OSA). Using a single-case experimental design (SCED) with multiple baselines, the study will investigate whether this respiratory intervention can reduce the severity of sleep apnea, as measured by the Apnea-Hypopnea Index (AHI), and improve inspiratory muscle strength and sleep quality. Participants will perform daily training sessions using a resistive loading device (POWERbreathe), with intensity progressing from 40% to 90% of their maximum inspiratory pressure.",[164,26,165],"Obesity, Class III","Inspiratory Muscle Training",[167,168,169,170],"Class III obesity","Inspiratory muscle training","Obstructive sleep apnea","Single-case experimental design","NOT_YET_RECRUITING","2026-03-18",{"date":174,"type":35},"2026-03-23",{"date":176,"type":20},"2026-05-01",{"date":178,"type":20},"2027-12-01",{"name":180,"class":42},"University of the State of Santa Catarina",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":43},"100576782","nasal-vs-oral-breathing-in-drug-induced-sleep-vs-natural-sleep-100576782","NCT06789770","Nasal vs Oral Breathing in Drug Induced Sleep vs Natural Sleep","The Impact of Nasal Versus Oral Breathing on Measures of Drug-Induced Sleep Endoscopy","Nasal vs Oral","Inclusion Criteria:\n\n* • Adults (≥ 18yrs) that underwent clinical evaluation at the CPAP Alternatives Clinic at Penn Otorhinolaryngology.\n\n  * Must have at least mild OSA (AHI\\>5)\n\nExclusion Criteria:\n\n* • Sleep study with an AHI\\\u003C5, \\>25% of total events being central or mixed events, or inability to achieve adequate drug-induced sleep.\n\n  * Upper Respiratory Illness at the time of the DISE.",{"count":190,"type":20},50,"OBSERVATIONAL","This project will provide important new information regarding (1) the relationship between route of breathing and airway collapsibility and (2) whether route of breathing during DISE (Drug-Induced Sleep Endoscopy) is representative of natural sleep.",[26],[195,196,197,198],"breathing route","OSA","nasal breathing","oral breathing","2026-03-10",{"date":201,"type":35},"2026-03-13",{"date":203,"type":35},"2024-11-20",{"date":205,"type":20},"2026-12",{"name":207,"class":42},"University of Pennsylvania",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":227,"locationsCount":229},"100568125","npa-osa-device-tolerability-usability-and-acclimation-clinical-study-in-adult-obstructive-sleep-apnea-osa-patients-100568125","NCT06677151","NPA-OSA Device Tolerability, Usability and Acclimation Clinical Study in Adult Obstructive Sleep Apnea (OSA) Patients","NPA-OSA Device Tolerability, Usability and Acclimation Clinical Study in Continuous Positive Airway Pressure (CPAP) Resistant Adult OSA Patients","Inclusion Criteria:\n\n* Capacity and willingness to sign consent\n* Patient willingness to commit to and complete study over a 30-day time period\n* Confirmed diagnosis of moderate to severe OSA (AHI \\>= 15)\n* OSA caused by upper airway obstruction\n* CPAP non-compliant where CPAP compliance is defined as using CPAP for at least 4 hours a night for at least 70% of nights or interest in an alternative sleep apnea therapy\n* Adequate manual dexterity to demonstrate ability to self-insert and remove device\n\nExclusion Criteria:\n\n* Within 3 months of initiating CPAP use, and actively using CPAP\n* Supraglottic airway collapse\n* Distal airway stenosis\n* Tracheobronchomalacia\n* Currently pregnant\n* Active COVID-19 infection\n* Need for anticoagulative therapy\n* Severe nasal allergies\n* Bleeding disorder\n* More than mild elevation of End-tidal carbon dioxide (ETCO2) or total carbon dioxide (TCO2) values \\>60 mmHg for \\>10% of sleep time\n* Restrictive thoracic disorders\n* Silicone, lidocaine, neosynephrine allergy\n* Recurrent epistaxis\n* Uncontrolled or serious illness, included but not limited to: severe breathing disorders including hypercapnic respiratory failure, respiratory muscle weakness, bullous lung disease (as seen in some types of emphysema), bypassed upper airway, pneumothorax, pneumomediastinum, etc.; severe heart disease (including heart failure); or pathologically low blood pressure",{"count":216,"type":20},20,[110],"This pilot study is being done to determine if the nasopharyngeal airway obstructive sleep apnea (NPA-OSA) device can be used in the treatment of OSA in adults. The researchers think that the NPA-OSA device will reduce the number of apneas.",[26],[221],"nasopharyngeal",{"date":223,"type":35},"2026-03-12",{"date":225,"type":35},"2025-03-07",{"date":205,"type":20},{"name":228,"class":42},"University of Michigan",2,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":43},"100627284","maxillomandibular-advancement-surgery-for-treatment-of-obstructive-sleep-apnoea-syndrome-100627284","NCT07446634","Maxillomandibular Advancement Surgery for Treatment of Obstructive Sleep Apnoea Syndrome","OSAS","Inclusion Criteria:\n\n* Clinical diagnosis of obstructive sleep apnea with AHI ≥15 events\u002Fh.\n* Residence and\u002For registration in Dalarna County\n* Body mass index (BMI; kg\u002Fm\\^2) between 15 and 35\n* Documented failure of CPAP or mandibular advancement therapy.\n\nExclusion Criteria:\n\n* Medical conditions contraindicating general anesthesia.\n* American Society of Anesthesiologists Physical Status (ASA) Class III-VI\n* Central sleep apnea\n* Narcolepsy\n* Prior orthognathic surgery\n* History of tumor disease or radiotherapy of the jaws. Participants with systemic conditions associated with an increased risk of OSA. Such risks include;\n* Hypothyroidism\n* Acromegaly\n* Diabetes mellitus\n* Active generalized rheumatoid arthritis\n* Clinically manifest periodic limb movement disorder\n* Restless legs syndrome.","70 Years",{"count":239,"type":20},48,[110],"This study looks at how jaw surgery called maxillomandibular advancement with counterclockwise rotation affects breathing during sleep in people with moderate to severe obstructive sleep apnea who cannot tolerate standard treatments such as Continous Positive Airway pressure treatment. The participants are followed over time to see whether the surgery improves sleep apnea symptoms, daytime sleepiness, and airway size, and whether these improvements last. Advanced three-dimensional imaging and airflow analysis are used to better understand how the surgery changes the airway and breathing. The goal is to evaluate the long-term effectiveness and safety of this surgical treatment.",[26],[83,244,245,246],"Orthognathic Surgical Procedure","Tomography","Computational Fluid Dynamics","2026-02-25",{"date":249,"type":35},"2026-03-03",{"date":251,"type":35},"2014-02-06",{"date":253,"type":20},"2032-06-30",{"name":255,"class":42},"Jani Talvilahti",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":16,"minAge":263,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":268,"conditions":269,"keywords":276,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":287,"locationsCount":289},"100483466","lateral-pharyngoplasty-outcomes-in-children-undergoing-tonsillectomy-100483466","NCT05575401","Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy","Post-operative Outcomes of Tonsillectomy With Lateral Pharyngoplasty Versus Tonsillectomy Alone in Children: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Participants ages 3-17 years of age undergoing tonsillectomy +\u002F- adenoidectomy at Loma Linda University Health\n\nExclusion Criteria:\n\n* Subjects with congenital syndromes and\u002For developmental delay\n* Subjects with cancer\n* Subjects with gastrostomy tube use or dependence\n* Subjects undergoing intracapsular tonsillectomy","3 Years","17 Years",{"count":266,"type":20},160,[110],"The goal of this treatment study is to determine if doing lateral pharyngoplasty with tonsillectomy is better for children than doing tonsillectomy alone. The main questions it aims to answer are:\n\n* Do children experience less pain after surgery when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone?\n* Do children eat\u002Fdrink better when lateral pharyngoplasty is performed with tonsillectomy compared to tonsillectomy alone?\n* Is there a lower risk of bleeding after tonsillectomy when lateral pharyngoplasty is performed? Researchers will compare children undergoing tonsillectomy and lateral pharyngoplasty with children undergoing tonsillectomy alone to see if the participants experience less pain, better oral intake, and less bleeding complications after surgery. Parents of participants will be asked to record pain scores and pain medications given, approximate amounts of daily oral intake, and any complications after surgery.",[270,271,26,272,273,274,275],"Sleep-Disordered Breathing","Sleep Apnea Syndromes in Children","Tonsillitis","Tonsillar Hypertrophy","Tonsil Stone","Tonsil Disease",[277,278,279,280],"Tonsillectomy","Post-tonsillectomy hemorrhage","Post-tonsillectomy complication","Lateral pharyngoplasty","2026-02-19",{"date":283,"type":35},"2026-02-23",{"date":285,"type":35},"2023-05-17",{"date":205,"type":20},{"name":288,"class":42},"Loma Linda University",4,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":16,"minAge":297,"maxAge":106,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":300,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":312,"locationsCount":43},"100579787","the-repose-reach-for-equity-in-pediatric-sleep-evaluation-navigation-intervention-100579787","NCT06828835","The REPOSE (Reach for Equity in Pediatric Sleep Evaluation) Navigation Intervention","Testing a Strategy to Improve Diagnostic and Treatment Pathways for Children With Sleep-Disordered Breathing: the REPOSE Navigation Intervention","Inclusion Criteria:\n\n* Parents or caregivers (18 and older) of children who were referred by any primary care for SDB evaluation with sleep medicine or pediatric otolaryngology\n* Patients 2.00 to 11.99 years old\n* Parents with a working phone who are willing to participate in the study for a 12-month period after enrollment\n\nExclusion Criteria:\n\n* Patients already established with sleep medicine or otolaryngology which would bias ease of completing specialty evaluation","2 Years",{"count":299,"type":20},80,[110],"This research study aims to find out the effect of REPOSE, a patient navigation intervention, on the receipt of equitable care among children with a broad range of socioeconomic and rural\u002Furban status with Sleep Disordered Breathing (SDB).\n\nIn the REPOSE intervention, a centralized patient navigator a) identifies and addresses dynamic individual barriers, b) provides resources and social support for parent-child dyads, and c) facilitates bidirectional SDB care coordination between clinical teams and parents to achieve evidence-based care.\n\nThis study will evaluate the effects of the REPOSE intervention on SDB care delivery and clinical process outcomes for children with a broad range of socioeconomic and rural\u002Furban status by reducing barriers and increasing self-efficacy among parents.",[26],[304,305],"Pediatrics","Sleep Disorders","2026-02-03",{"date":308,"type":35},"2026-02-05",{"date":306,"type":35},{"date":311,"type":20},"2028-08-31",{"name":313,"class":42},"Medical University of South Carolina",{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":43},"100586473","type-1-diabetes-and-obstructive-sleep-apnea-100586473","NCT06915831","Type 1 Diabetes and Obstructive Sleep Apnea","Obstructive Sleep Apnea and Glycemic Dysregulation in Adults With Type 1 Diabetes","T1D and OSA","Inclusion Criteria:\n\n* Age: 18 to 50 years old\n* Type 1 Diabetes on insulin pump therapy and using a CGM device with an GMI (glucose management indicator) between 5.5 and 8.5% with hemoglobin in the normal range at screening\n* OSA by home sleep apnea test\n\nExclusion Criteria:\n\n* Regular and adherent CPAP use per clinical guidelines\n* Requiring oxygen or advanced positive airway pressure modalities during sleep\n* Having a 'fall-asleep' or 'near miss' accident in the past 6-months\n* Shift work\n* Severe hypoglycemia (≥1 episode in the past 3 months or diagnosis of hypoglycemic unawareness)\n* ≥1 trip to emergency room for poor glucose management in the past 6 months\n* Proliferative retinopathy\n* Fasting triglycerides \\>400mg\u002FdL,\n* Liver transaminases \\>2 times upper limit of normal,\n* Renal transplantation or serum creatinine \\>1.5 mg\u002FdL\n* Anemia (hemoglobin \\\u003C13.0g\u002FdL in men or \\\u003C11.6g\u002FdL in women)\n* Acute coronary syndrome or stroke past 6 months\n* Severe hypertension (blood pressure\\>180\u002F105 mmHg)\n* Any other significant health condition: unstable angina, heart failure requiring hospitalization in the past 6 months, significant heart block or arrhythmias, NYHA Class\\>2, pulmonary disease with dependence on oxygen or daily use of bronchodilators, active or chronic infection, thyroid disease and other endocrine disorders (e.g. Cushing syndrome, acromegaly)\n* Recent major surgery\n* Major psychiatric disorder\n* Subjects will also be excluded if taking medications that can confound metabolic assessments including systemic glucocorticoids, antipsychotics, thiazide diuretics, beta-blockers, daily use of aminophylline or theophylline, or use of any immunosuppressant.\n* Currently pregnant or trying to get pregnant or nursing\n* Smoking, alcohol or illegal drug abuse","50 Years",{"count":78,"type":20},[110],"The purpose of the study is to investigate the role of sleep apnea in glycemic dysregulation in adults with Type 1 diabetes.",[26,327],"Type 1 Diabetes (T1D)","2026-01-15",{"date":330,"type":35},"2026-01-20",{"date":332,"type":35},"2025-11-10",{"date":334,"type":20},"2029-08-31",{"name":336,"class":42},"University of Chicago",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":344,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":347,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":229},"100294151","accuracy-of-the-sensory-test-using-the-laryngopharyngeal-endoscopic-esthesiometer-in-obstructive-sleep-apnea-100294151","NCT03109171","Accuracy of the Sensory Test Using the Laryngopharyngeal Endoscopic Esthesiometer in Obstructive Sleep Apnea","Accuracy of the Sensory Test Performed Using the Laryngopharyngeal Endoscopic Esthesiometer and Rangefinder in Patients With Suspected Obstructive Sleep Apnoea Hypopnea (OSA): a Prospective Double-blinded, Randomised, Pilot Study","Inclusion Criteria:\n\n* Patients being 18 years old or more referred to the sleep laboratory of a tertiary care university hospital for a baseline polysomnography for suspected OSA.\n\nExclusion Criteria:\n\n* Anticoagulation (though not a contraindication for the endoscopic laryngopharyngeal sensory test, anticoagulation is an exclusion criteria for this validation study in order to keep it a minimal-risk study).\n* Bleeding diathesis.\n* Basal awake oxygen saturation by pulse oximetry below 88%.\n* Not agree to participate in the study.\n* Glasgow coma scale below of 15 (to avoid confusion with involvement of laryngopharyngeal reflexes due to neurological disease accompanied by decreased level of consciousness).\n* Baseline polysomnography that does not meet validity criteria to be interpreted (according to the American Academy of Sleep Medicine).\n* Baseline polysomnography performed more than 15 days before the sensory testing. Ordinarily, the sensory testing will be performed the same day or the next day of baseline polysomnography.\n* More than 5% of total apnoea events being of central origin.\n* History of maxillofacial or pharyngeal surgery (to avoid confusion with involvement of laryngopharyngeal reflexes due to surgery in this region).\n* Laryngopharyngeal tract malignancies (to avoid confusion with involvement of laryngopharyngeal reflexes due to tumours).\n* Central Nervous System (CNS) surgery in the last three months or that has left neurological sequelae (to avoid confusion with involvement of laryngopharyngeal reflexes due to sequelae of CNS surgery).\n* Traumatic brain injury in the last three months or more than three month with neurological sequelae.\n* History of active neuromuscular disease that affects the muscles of head and neck or with sequels present at the time of the sensory testing (to avoid confusion with involvement of laryngopharyngeal reflexes due to neuromuscular disease).\n* History of cerebrovascular disease (to avoid confusion with dysphagia or sensory compromise secondary to cerebrovascular disease).\n* Diabetes (to avoid confusion with diabetic neuropathy that compromises the laryngopharyngeal region).\n* Chronic use of systemic corticosteroids at a dose greater or equal to 20 mg per day of prednisone or equivalent (to avoid confusion with steroid myopathy that compromises the laryngopharyngeal region).\n* Upper respiratory tract infection within 15 days prior to the testing (to avoid confusion with neuropathy associated with respiratory viral disease that compromises the laryngopharyngeal region).\n* Patient's inability to cooperate during the examination (to avoid measurement error caused by the lack of cooperation of the patient).",true,{"count":346,"type":20},117,[110],"This is a prospective double blinded randomized crossover controlled trial aiming at validating the measurement of laryngopharyngeal mechanosensitivity in patients with suspected OSA using a recently developed laryngopharyngeal endoscopic esthesiometer and rangefinder (LPEER).\n\nSubjects will be recruited from patients with suspected OSA referred for baseline polysomnography to a university hospital sleep laboratory. Intra- and inter-rater reliability will be evaluated using the Bland-Altman's limits of agreement plot, the intraclass correlation coefficient, and the Pearson or Spearman correlation coefficient, depending on the distribution of the variables. Diagnostic accuracy will be evaluate plotting Receiver-operating-characteristic-curves (ROC-curves) using as reference standard basal polysomnogram. The sensory threshold values for patients with mild, moderate, and severe OSA, will be determined and compared using ANOVA or Kruskal Wallis test, depending on the distribution of the variables.",[26,350,351],"Larynx","Sensory Disorder",[353,354,355,356,357,358,359,360,361,362,363,364],"Endoscopy","Lasers","Fiber Optic Technology","Bronchoscopy","Esthesiometer","Mechanoreceptors","Diagnosis","Reflex","Reproducibility of Results","Reliability of Results","Validity of Results","Sensory Thresholds","2026-01-06",{"date":367,"type":35},"2026-01-08",{"date":369,"type":35},"2018-01-01",{"date":371,"type":20},"2026-11-30",{"name":373,"class":42},"Fundación Neumologica Colombiana",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":43},"100472292","predicting-outcomes-in-hypoglossal-nerve-stimulation-therapy-with-stimulated-upper-airway-mechanics-100472292","NCT05429983","Predicting Outcomes in Hypoglossal Nerve Stimulation Therapy With Stimulated Upper Airway Mechanics","Assessing Stimulated Upper Airway Mechanics to Predict Outcomes in Hypoglossal Nerve","Inclusion Criteria:\n\n* Male and female participants with moderate or severe sleep apnea (defined by \\> 15 apneas and hypopneas per hour of sleep), who are undergoing DISE as part of routine evaluation for Inspire hypoglossal nerve stimulation therapy or for ineffective HGNS therapy.\n\nExclusion Criteria:\n\n* Significant cardiac disease, unstable or recent cardiac events\n* Active pulmonary, liver or renal disease\n* Uncontrolled hypertension (BP\\>160\u002F100)\n* Neuromuscular disease\n* Major psychiatric disease\n* Pregnancy\n* Anticoagulation therapy (e.g. Coumadin, Dabigatran)",{"count":382,"type":20},60,"Obstructive sleep apnea (OSA) is a highly prevalent disease resulting from dynamic upper airway collapse during sleep. Continuous positive airway pressure (CPAP) is highly efficacious but high rates of non-adherence to CPAP leaves large number of OSA patients at risk for cardiometabolic sequelae. Inspire™ is an FDA-approved hypoglossal nerve stimulation device (HGNS) used in select patients with OSA who are intolerant of CPAP. The device consists of an implanted impulse generator with a stimulating cuff lead around the distal hypoglossal nerve. Despite these stringent selection criteria, up to one-third of patients implanted have inadequate responses to HGNS and remain at risk for complications from untreated OSA. The current proposal builds on routine clinical care to characterize upper airway biomechanics and determine predictors of clinical responses to HGNS therapy.\n\nDrug induced sleep endoscopy (DISE) is a prerequisite for HGNS treatment and represents an ideal opportunity to rapidly characterize upper airway dynamics under controlled, standardized conditions. The amount of nasal pressure required to relieve airway obstruction (minimal therapeutic pressure) is a significant predictor of successful treatment of OSA with HGNS. As a result, CPAP titration (measuring pharyngeal collapse patterns at varying nasal pressures) has become an integral part of DISE to select parties for HGNS at multiple institutions. Nevertheless, changes in upper airway collapsibility in response HGNS may differ significantly between patients. This stud will examine if changes in upper airway patency with direct genioglossus muscle stimulation at the time of DISE predicts successful treatment with HGNS as defined by a 50% reduction on apnea-hypopnea index (AHI) and an on-treatment AHI \\\u003C20.",[26],"2025-12-23",{"date":387,"type":35},"2025-12-24",{"date":389,"type":35},"2022-11-29",{"date":391,"type":20},"2028-11-29",{"name":393,"class":42},"Johns Hopkins University",{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":229},"100607650","long-term-evaluation-of-a-nasopharyngeal-airway-100607650","NCT07191314","Long-term Evaluation of a Nasopharyngeal Airway","Inclusion Criteria:\n\n-Participants who completed the parent study (HUM00179497) and wish to continue using the NPA-OSA device.\n\nExclusion Criteria:\n\n* The participants who were non-compliant with the NPA-OSA device during their participation in the parent study.",{"count":216,"type":20},[110],"This long-term follow-up study will permit continued device use for participants of the parent study (NCT06677151).\n\nDuring study participation the study team will stay in contact with participants as necessary. Additionally, patients will undergo clinical follow-up as needed with their physician(s). At 12 months, participants will complete sleep questionnaires as part of this long-term follow-up period.",[26],[221],"2025-11-05",{"date":407,"type":35},"2025-11-06",{"date":409,"type":35},"2025-10-21",{"date":411,"type":20},"2027-09",{"name":228,"class":42},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":16,"minAge":263,"maxAge":421,"enrollmentInfo":422,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":43},"100590938","is-change-in-mouth-opening-related-to-change-in-quality-of-life-in-children-with-type-1-obstructive-sleep-apnea-after-adenotonsillectomy-100590938","NCT06973928","Is Change in Mouth Opening Related to Change in Quality of Life in Children With Type 1 Obstructive Sleep Apnea After Adenotonsillectomy?","Is Change in Mouth Opening Related to Change in Quality of Life in Children With Type 1 Obstructive Sleep Apnea After Adenotonsillectomy? The JawChild Prospective Cohort Study","JawChild","Inclusion Criteria:\n\n* Age: 3 to 7 years old\n* Received a surgical indication for adenotonsillectomy\n* Beneficiary of the French single-payer national medical insurance system\n* Informed consent given\n* Able to attend all scheduled visits and comply with all trial procedures.\n\nExclusion Criteria:\n\n* Previous adenotonsillectomy\n* Subject has already participated in the current study\n* Craniofacial malformation syndrome\n* BMI according to age \\> 97th percentile\n* Previous or current stimulant medication (methylphenidate)\n* Current orthodontic treatment\n* Asymmetric score of the tonsil with a tonsil Brodsky score of ≤2\n* Subject who are in a dependency or employment with the sponsor or the investigator\n* Participation in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date","7 Years",{"count":190,"type":20},"The goal of this clinical trial is to learn if changes in quality of life are linked to changes in mouth opening after adenotonsillectomy in a group of children who were diagnosed with Type 1 Obstructive Sleep Apnea (OSA1). The main questions it aims to answer are:\n\nPrimary Objective:\n\n•Are changes in quality of life linked to improvements in mouth opening after adenotonsillectomy?\n\nSecondary Objectives:\n\n* How does quality of life change after adenotonsillectomy, based on different questionnaires about the child's sleep, breathing, behavior, and emotions?\n* Is there a link between changes in quality of life and changes in mouth movements after adenotonsillectomy?\n* Is there a link between changes in quality of life and changes in sleep quality after adenotonsillectomy?\n* How do clinical symptoms change after adenotonsillectomy?\n* Are measures of mouth movements linked to measurements of sleep quality after adenotonsillectomy?\n\nParticipation will require:\n\n* Participating children will have adenotonsillectomy surgery, as suggested by their doctor\n* Before and after tonsillectomy, parents of participating children will answer questionnaires related to their child's quality of life and their child's symptoms related to sleep, breathing, behavior, and emotions\n* Sleep quality and mouth opening will be evaluated in participating children before and after tonsillectomy",[26],[426,427,428,429],"type 1 obstructive sleep apnea","adenotonsillectomy","mouth opening","Polysomnography","2025-09-30",{"date":432,"type":35},"2025-10-03",{"date":434,"type":20},"2025-10-15",{"date":436,"type":20},"2026-10-15",{"name":438,"class":42},"Groupe Adène",{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":16,"minAge":446,"maxAge":17,"enrollmentInfo":447,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":461,"locationsCount":43},"100606531","the-ipad-cohort-study-insomnia-and-positive-airway-pressure-adherence-in-children-and-adolescents-100606531","NCT07176767","The IPAD Cohort Study: Insomnia and Positive Airway Pressure Adherence in Children and Adolescents","IPAD","Inclusion Criteria:\n\n1. Children aged 8-18 years old\n2. Obstructive apnea-hypopnea index ≥ 5\u002Fhour on baseline diagnostic polysomnogram (PSG)\n3. Newly prescribed PAP therapy\n\nExclusion Criteria:\n\n1\\) Developmental disability precluding ability to answer questionnaires","8 Years",{"count":448,"type":20},82,"Positive Airway Pressure (PAP) is a treatment used to help people with sleep-disordered breathing, particularly those with obstructive sleep apnea (OSA). The device delivers pressurized air through a mask to keep the airways open during sleep, improving breathing and preventing interruptions in sleep.\n\nStudying how insomnia affects PAP adherence in children can help improve future treatments.\n\nHowever, no long-term studies have looked at this in children. Based on previous research, the investigators plan to conduct a study across multiple centers focusing on children with OSA starting PAP therapy. The study will explore how insomnia affects PAP adherence and how race and ethnicity play a role.",[26,451],"Insomnia",[28,451,453,454],"Pediatric Sleep","Positive Airway Pressure Adherence","2025-09-17",{"date":457,"type":35},"2025-09-23",{"date":459,"type":35},"2025-06-12",{"date":94,"type":20},{"name":462,"class":42},"Lena Xiao",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":470,"enrollmentInfo":471,"targetDuration":4,"studyType":21,"phases":473,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":43},"100522975","phase-4-cpap-effect-on-the-polycythemia-in-patients-with-obstructive-sleep-apnea-100522975","NCT06089603","CPAP Effect on the Polycythemia in Patients With Obstructive Sleep Apnea","PoliAOS","Inclusion Criteria:\n\n* Subjects from 18 to 80 years old.\n* Diagnosis of polycytemia defined as hematocrit \\> 49% in men and \\> 48% in women. ç\n* Diagnosis of moderate or severe sleep apnea, defined by an apnea-hypoapnea index \\>15. - Patients able to read and understand informed consent and give their signed consent.\n\nExclusion Criteria:\n\n* Smokers or former smokers with pack-year index (IPA\\>30) or chronic obstructive pulmonary disease diagnosed by spirometry (FEV1\u002FFVC post-bronchodilator below the lower limit of normal or z score \\\u003C 1.645).\n* Patients with central sleep apnea or periodic breathing\n* Patients with oxygen saturation \\\u003C92% or pO2\\\u003C 60 mmHg at rest during wakefulness. - Evidence of severe heart failure (LVEF\\\u003C50) or pulmonary hypertension.\n* Patients with primary polyglobulia (polycythemia vera). It will be done prior to the inclusion in the study blood levels of erythropoietin (EPO) and determination of the mutation of the JAK2 V617F gene. Patients with normal or elevated EPO levels (normal limits 2.9- 25.9 mU\u002Fml) and no JAK2 V617F gene mutation\n* Patients with any active neoplasm will be included in the study. - Patients with chronic kidney disease (Glomerular Filtration Rate (GFR) \\\u003C60 mL\u002Fmin\u002F1.73 m2).\n* Patients with any active neoplasia.- Patients with chronic kidney disease (Glomerular Filtration Rate (GFR) \\\u003C60 mL\u002Fmin\u002F1.73 m2).\n* Need for periodic bleeding according to hematology guidelines.\n* Treatment with diuretics.\n* Treatment with antiplatelets or anticoagulants.\n* Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg at the baseline visit.\n* Stroke, transient ischemic attack, acute coronary syndrome or hospitalization due to worsening heart failure, in the previous 30 days .\n* Professional drivers, high-risk profession or respiratory failure (according to criteria of the clinical path of diagnosis and treatment of sleep-related respiratory disorders).\n* High daytime sleepiness (Epworth sleepiness scale \\> 16)\n* Previous treatment with CPAP- Participation in another clinical trial within 30 days prior to randomization.","80 Years",{"count":472,"type":20},182,[474],"PHASE4","Objectives: To compare the response of polycythemia in terms of hematocrit decrease in patients treated with positive airway pressure (CPAP) versus patients not treated with CPAP.\n\nMethodology: Randomized, parallel-group, nonblinded, controlled clinical trial.\n\nPatients diagnosed with OSA in a respiratory polygraphy (RP) and who meet all the inclusion criteria and none of the exclusion criteria will undergo sleepiness and quality of life questionnaires, anthropometric measurements and blood tests and will be randomized to a CPAP treatment group or control group, maintaining this treatment for 12 months. A visit will be made at 12 weeks ,24 weeks and 52 weeks to check compliance with CPAP in the treatment group and to carry out questionnaires on physical activity and quality of life, anthropometric measurements, blood tests including hemoglobin and hematocrit as well as parameters related to coagulation and platelet function and changes in medication as well as adverse effects.\n\nEfficacy variables: blood count, hemoglobin, haematocrit, erythropoietin, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), mean platelet volume (MPV), platelets, coagulation, erythrocyte range of distribution (ADE), glucose, creatinine, glomerular filtration rate, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyltransferase (GGT), Total bilirubin, hypoxic burden, Epworth score, EuroQol- 5D questionnaire.",[26,477],"Polycythemia","2025-09-11",{"date":455,"type":35},{"date":481,"type":35},"2023-11-01",{"date":483,"type":20},"2026-09",{"name":485,"class":42},"Hospital Universitario Ramon y Cajal",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":344,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":21,"phases":493,"briefSummary":494,"conditions":495,"keywords":496,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":505,"locationsCount":43},"100477454","phase-1-use-of-passive-myofunctional-appliances-for-snoring-and-mild-obstructive-sleep-apnea-100477454","NCT05497180","Use of Passive Myofunctional Appliances for Snoring and Mild Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Patients diagnosed with mild obstructive sleep apnea or snoring without sleep apnea.\n* Patients 18 years or older\n* Patients able to provide consent to treatment and participation in the study\n\nExclusion Criteria:\n\n* Patients previously diagnosed as non-responders to oral appliance therapy for their sleep apnea\n* Patients undergoing other active therapies for their sleep apnea\n* Patients with a history of airway\u002Fsleep breathing surgical interventions\n* Participants with a history of airway\u002Fsleep breathing surgical intervention are not eligible to be a part of this study do to risk of skewing test results\n* Patients with craniofacial, syndromic, or neuromuscular disorders\n* Patients with acute medical conditions requiring immediate attention\n* Participants with an acute medical problem will be immediately referred to an appropriate physician and will not be allowed to enroll in the study until their health conditions are stable.",{"count":78,"type":20},[80],"It is unknown whether passive myofunctional appliances can be used for the treatment of obstructive sleep apnea and snoring, nor how to select the appropriate size per individual patient. Exploring the possibility of using passive myofunctional appliances as a treatment option for patients with mild obstructive sleep apnea and\u002For snoring should be considered, especially as the time to fabricate and deliver custom designed dental sleep appliances can be significant (sometimes over a month). Use of passive myofunctional appliances as a transitional appliance or potentially as direct treatment for obstructive sleep apnea may significantly decrease time to treatment and also provide a less expensive treatment option for patients with obstructive sleep apnea. The purpose of this study is to determine whether passive myofunctional appliances can be used as a treatment option for patients suffering from snoring and mild obstructive sleep apnea (OSA).",[26],[497,498],"Mandibular Advancement Devices","Myofunctional Therapy","2025-08-20",{"date":501,"type":35},"2025-08-21",{"date":503,"type":35},"2022-07-23",{"date":125,"type":20},{"name":506,"class":42},"University of Alberta",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":16,"minAge":514,"maxAge":4,"enrollmentInfo":515,"targetDuration":4,"studyType":21,"phases":517,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100600278","assessing-the-performance-of-wesper-lab-for-obstructive-and-central-sleep-apnea-100600278","NCT07095413","Assessing the Performance of Wesper Lab for Obstructive and Central Sleep Apnea","Assessing the Performance of Wesper Lab for Obstructive and Central Sleep Apnea Diagnosis in Adult Populations","Inclusion Criteria:\n\n* Be at least 21 years of age\n* Have a referral to the study site from a physician to complete an overnight polysomnogram test for sleep apnea detection or follow-up.\n* Be willing and able to wear two Wesper Lab patches and an FDA-cleared pulse oximeter in conjunction with a polysomnogram, for a single night.\n* Be able and voluntarily willing to sign a written informed consent form prior to the initiation of any study procedures. Adult patients unable to provide written informed consent on their own behalf will not be eligible for the study.\n\nExclusion Criteria:\n\n* Women who are pregnant, trying to get pregnant or who have a positive urine pregnancy test on the day of the study.\n* Women who are breast-feeding\n* History of severe insomnia\n* Any known health condition that, in the opinion of the Investigator, would exclude the patient from participating in the study.","21 Years",{"count":516,"type":20},100,[110],"The goal of this clinical trial is to evaluate the effectiveness of the Wesper Lab home sleep apnea test as a tool to aid in the diagnosis of sleep apnea in adult patients (age ≥21 years) who are recommended for an overnight polysomnography (PSG) evaluation. The main questions it aims to answer are:\n\n1. Is Wesper Lab home sleep apnea test as accurate as an in-laboratory sleep study (polysomnography) for the diagnosis of obstructive and central sleep apnea?\n2. Is Wesper Lab accurate in a wide range of body types and skin types?\n\nParticipants will:\n\n1. Provide informed consent and complete a brief medical history.\n2. Undergo an overnight polysomnography sleep study while wearing two Wesper Lab patches and a compatible pulse oximeter.\n3. Have a follow-up communication within 5 days post-study to assess any adverse events.",[83,26,520],"Sleep Apnea, Central","2025-07-23",{"date":523,"type":35},"2025-07-31",{"date":525,"type":20},"2025-09-01",{"date":527,"type":20},"2026-02-01",{"name":529,"class":68},"Wesper Inc",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":16,"minAge":537,"maxAge":136,"enrollmentInfo":538,"targetDuration":540,"studyType":191,"phases":4,"briefSummary":541,"conditions":542,"keywords":543,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":43},"100417205","effects-of-cpap-therapy-on-blood-pressure-and-heart-rate-variability-in-obstructive-sleep-apnea-100417205","NCT04712656","Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea","Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea: Role of Symptom Subtypes","Inclusion Criteria:\n\n* 30 to 75 years of age\n* Among patients with hypertension, no change in BP medication for at least 3 months.\n* Willing and able to give informed consent\n* Willing and able to complete ambulatory blood pressure monitoring at baseline and after 6-months.\n* Sleep study \\[Polysomnography (PSG) or Home Sleep Apnea Study (HSAT) performed based on clinical grounds\n* 4% oxygen desaturation index (ODI4) ≥15 events\u002Fhour on clinical sleep study\n* Planned CPAP treatment by treating provider\n\nExclusion Criteria:\n\n* Unable to apply BP cuff (e.g. arm circumference \\>55 cm, prior breast cancer, structural abnormalities of the arm)\n* Current use of CPAP or Dental Device for OSA\n* Category III-IV of heart failure\n* Presence of Cheyne-Stokes Respiration (CSR) in PSG\n* Predominantly central sleep apnea (AHI≥15 events\u002Fhour)\n* Pregnancy\n* History of renal failure, or renal transplant\n* Self-reported sleep duration less than 5 hours per night on weeknights (work nights)\n* Other sleep disorders\n* Use of supplemental oxygen during wakefulness or sleep\n* Self-reported illicit drug use or marijuana use more than once per week\n* Unstable medical conditions: uncontrolled angina, uncontrolled hypertension, severe chronic obstructive pulmonary disease, active cancer, or unstable psychiatric disease\n* Any underlying condition that, in the opinion of the lead investigator, prohibits participation in the study\n* Development or adoption of any of the above exclusion criteria during the study period","30 Years",{"count":539,"type":20},1739,"10 Years","The primary objective of this study is to determine whether the effect of continuous positive airway pressure (CPAP) therapy on 24-hour mean blood pressure (BP) in patients with obstructive sleep apnea (OSA) varies between symptom phenotypes.",[26],[544],"Cardiovascular","2025-07-21",{"date":547,"type":35},"2025-07-24",{"date":549,"type":35},"2021-03-22",{"date":551,"type":20},"2032-03-01",{"name":553,"class":42},"Ohio State University",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":470,"enrollmentInfo":561,"targetDuration":4,"studyType":21,"phases":563,"briefSummary":564,"conditions":565,"keywords":569,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":43},"100593036","effect-of-cpap-versus-apap-in-patients-with-obesity-undergoing-bariatric-surgery-protocol-100593036","NCT07001215","Effect of CPAP Versus APAP in Patients With Obesity Undergoing Bariatric Surgery Protocol","ObesAOS","Inclusion Criteria:\n\n* Subjects aged 18 to 80 years who meet the criteria for bariatric surgery and are on the surgical waiting list after approval by the bariatric surgery committee (BMI ≥35, or BMI ≥30 with comorbidities).\n* Diagnosis of moderate or severe sleep apnea, defined by an Apnea-Hypopnea Index (AHI) \\>15, requiring treatment according to protocol (\"Patients with an AHI of 15 or higher will be treated with CPAP if they have hypertension, excessive daytime sleepiness, or sleep-related symptoms not explained by other causes\" \\[17\\]).\n* Patients must be able to read and understand the informed consent and provide signed consent.\n\nExclusion Criteria:\n\n* Patients with central sleep apnea or periodic breathing\n* Patients with any active neoplasm\n* Patients with severe uncontrolled psychiatric disorders, alcoholism, or active drug addiction\n* Patients with unacceptable surgical\u002Fanesthetic risk\n* Patients who have undergone previous surgery for OSA or who have been treated with positive airway pressure and did not tolerate it",{"count":562,"type":20},104,[110],"Introduction Obstructive sleep apnea (OSA) is a common disorder in obese patients, especially those undergoing bariatric surgery. OSA is characterized by upper airway obstruction during sleep, leading to intermittent hypoxia and sleep fragmentation. Obesity and OSA are closely related conditions that can exacerbate each other. Positive airway pressure therapy is essential for managing OSA, but adherence to therapy can be challenging, particularly in patients who experience rapid physiological changes after bariatric surgery.\n\nObjective This study aims to determine whether automatic positive airway pressure therapy (APAP) improves nightly usage hours compared to continuous positive airway pressure therapy (CPAP) in obese patients undergoing bariatric surgery. Secondary objectives include evaluating the percentage of nights with therapy use over 4 hours, reduction of the residual apnea-hypopnea index (AHI), changes in daytime sleepiness, pressure requirements, side effects, sleep-related quality of life, reduction in in-person visits, and optimization of healthcare resources.\n\nMethodology A randomized, parallel-group, open-label, controlled clinical trial will be conducted. Adult patients eligible for bariatric surgery with a diagnosis of moderate to severe OSA (AHI \\> 15) requiring positive pressure therapy will be included. Participants will be randomized to receive either APAP or CPAP. Follow-up will be conducted over 12 months after surgery, with assessments at 3, 6, and 12 months. Data will be collected on treatment adherence, residual AHI, OSA symptoms, daytime sleepiness, quality of life, and treatment costs.\n\nAPAP therapy is expected to improve nightly usage hours compared to CPAP. It is also expected that APAP will show better adaptation to changing pressure needs after bariatric surgery. Data will be analyzed to evaluate the effectiveness and cost-efficiency of both therapies.\n\nThis study will provide evidence on the efficacy of APAP compared to CPAP in obese patients undergoing bariatric surgery. The results will help optimize the treatment of OSA in this population and improve patients' quality of life. Additionally, the study is expected to contribute to the optimization of healthcare resources by reducing in-person visits and repeated sleep studies.",[26,566,57,567,568],"Bariatric Surgery","Treatment Adherence and Compliance","Continuous Positive Airway Pressure (CPAP)",[570,568,571,566,57],"Obstructive Sleep Apnea (OSA)","Automatic Positive Airway Pressure (APAP)","2025-07-17",{"date":521,"type":35},{"date":575,"type":20},"2025-09-15",{"date":577,"type":20},"2028-09-15",{"name":485,"class":42},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":470,"enrollmentInfo":587,"targetDuration":4,"studyType":21,"phases":589,"briefSummary":590,"conditions":591,"keywords":595,"overallStatus":171,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":43},"100596247","peri-operative-bipap-to-prevent-tracheostomy-in-high-risk-bilateral-vocal-cord-paralysis-bvcp-100596247","NCT07042971","Peri-operative BiPAP to Prevent Tracheostomy in High-Risk Bilateral Vocal-Cord Paralysis (BVCP)","A Multicenter, Randomized Controlled Trial of Pre-operative BiPAP Training and Post-extubation BiPAP Support to Reduce Peri-operative Tracheostomy or Re-intubation in Patients at High Risk for Bilateral Vocal-Cord Paralysis","BVCP-BiPAP","Inclusion Criteria:\n\n* Age 18 - 80 years.\n* Scheduled for thyroidectomy or other neck surgery under general anesthesia.\n* High risk of bilateral vocal-cord paralysis (BVCP) defined by at least ONE of:\n\n  * Pre-operative flexible laryngoscopy showing fixed vocal cords at midline or paramedian position, or glottic gap ≤ 3 mm; OR\n  * Presence of ≥ 2 high-risk factors:\n\n    * Planned bilateral central plus lateral neck dissection\n    * Re-operative bilateral neck surgery or dense scarring\n    * Tumor involving both recurrent laryngeal nerves or crico-arytenoid joints\n    * Severe obstructive sleep apnea (AHI ≥ 30 events\u002Fhour)\n    * Body-mass index (BMI) ≥ 30 kg\u002Fm²\n* Able to tolerate and give informed consent for BiPAP mask use.\n\nExclusion Criteria:\n\n* Emergency surgery or need for immediate tracheostomy.\n* Existing tracheostomy or home ventilator dependence.\n* Inability to protect airway (e.g., Glasgow Coma Scale \\\u003C 13).\n* Craniofacial anomaly or skin condition precluding mask seal.\n* Pregnancy or breastfeeding.\n* Participation in another interventional trial that could interfere with study endpoints.",{"count":588,"type":20},204,[110],"Why: After thyroid or neck surgery, some patients can lose movement of both vocal cords (bilateral vocal-cord paralysis, BVCP). This can make breathing difficult and often leads to an emergency or preventive tracheostomy (\"wind-pipe\") surgery.\n\nWhat: This study will test two simple ways to avoid a tracheostomy:\n\nPre-operative BiPAP sleep training - patients practice sleeping with a non-invasive BiPAP breathing machine for seven nights before surgery so they become comfortable with the mask and pressures.\n\nImmediate post-extubation BiPAP support - the same BiPAP machine is started as soon as the breathing tube is removed in the operating room or recovery area.\n\nHow: Adults (18-80 years) who already have, or are at high risk of getting, BVCP will be randomly assigned to one of four groups in a 2 × 2 design:\n\n• Group 1: training + post-op BiPAP • Group 2: training only • Group 3: post-op BiPAP only • Group 4: standard care (no planned BiPAP).\n\nMain goal: To find out whether either or both BiPAP strategies reduce the need for tracheostomy or re-intubation during the first 7 days after surgery.\n\nWhat participants do: Eligible patients will undergo routine surgery plus the assigned BiPAP plan. Breathing events, comfort, hospital stay, and voice quality will be recorded up to 6 months.\n\nPotential benefit\u002Frisk: BiPAP is non-invasive and already FDA-cleared for home and hospital use, but some people may feel mask discomfort or air leaks. Trained staff will adjust settings and stop BiPAP if serious problems occur.",[592,593,594,26],"Vocal Cord Paralysis, Bilateral","Airway Obstruction, Postoperative","Thyroid Neoplasms",[596,597,85,598,599,600,601,602,603,604],"BiPAP","Non-invasive Ventilation","Peri-operative Airway Management","Tracheostomy Avoidance","Thyroidectomy","Neck Surgery","Glottic Stenosis","Pre-operative Sleep Training","Voice Handicap Index","2025-06-27",{"date":607,"type":35},"2025-06-29",{"date":609,"type":20},"2025-07-01",{"date":611,"type":20},"2029-12-31",{"name":613,"class":42},"Fujian Medical University",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":622,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":624,"conditions":625,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":43},"100581310","treatment-of-sleep-apnea-to-improve-metabolic-health-100581310","NCT06848647","Treatment of Sleep Apnea to Improve Metabolic Health","Treatment of Sleep Apnea to Improve Metabolic Health - a Novel Approach to Unanswered Questions","GLYCOSACT","Inclusion Criteria:\n\n* Patients diagnosed with obstructive sleep apnea\n* Planned for CPAP treatment\n* 18 years and above\n\nExclusion Criteria:\n\n* Patient not wanting to participate in study\n* Non-Swedish speaking\n* Judged by physician as non-fit for study participation",{"count":623,"type":20},600,"Diabetes and prediabetes prevail among obstructive sleep apnea (OSA) patients. OSA and short sleep both detrimentally affect glycemic control regardless of obesity. With 1 in 10 adults having diabetes, 1 in 10 with prediabetes, and an estimated 600,000 affected by OSA in Sweden, attaining glycemic control is crucial. Though continuous positive airway pressure (CPAP) is the most effective treatment for OSA, its application lacks personalization, ignoring factors like comorbidities and sleep duration. Key unanswered questions regarding CPAP's impact on glycemic control include: 1) Does high CPAP adherence optimize glycemic control? 2) Should short sleep be addressed alongside OSA treatment for glycemic control? 3) Does long-term diabetes hinder CPAP's glycemic control efficacy? The purpose of this project is to enable precision health in CPAP treatment and producing a personalized treatment model for achieving glycemic control in patients with OSA, treated with CPAP. Taking advantage of a large unique patient cohort (600 patients followed over 18 months) with extensive and objective measures on CPAP adherence, OSA reduction, sleep duration, as well as information on comorbidities, anthropometric, lifestyle data, and a wide range of biomarkers related to glycemic control. This comprehensive approach and in-depth analysis will address these questions and generate a personalized treatment strategy for glycemic control in CPAP-treated OSA patients.",[26,626,86,627],"Metabolism","Patients Above 18 Years","2025-02-26",{"date":630,"type":35},"2025-02-27",{"date":632,"type":35},"2024-05-13",{"date":634,"type":20},"2028-12-31",{"name":636,"class":42},"Uppsala University",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":644,"enrollmentInfo":645,"targetDuration":4,"studyType":21,"phases":647,"briefSummary":648,"conditions":649,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":43},"100358538","normotensive-osa-patients-with-dipper-circadian-blood-pressure-pattern-100358538","NCT03948373","Normotensive OSA Patients With Dipper Circadian Blood Pressure Pattern","CPAP Effect in Nocturnal Blood Pressure in Normotensive Patients With Dipper Circadian Pattern and Severe Obstructive Sleep Apnea (OSA)","Inclusion Criteria:\n\n1. Men and women over 18 years of age\n2. Referred to the sleep unit for suspected OSA\n3. Being normotensive and presenting an AHI ≥ 30 in the sleep study\n4. Signature of the informed consent.\n\nExclusion Criteria:\n\n1. Previous CPAP treatment\n2. Significant somnolence defined by an Epworth Sleepiness Scale (ESS) score higher than 18\n3. Psychophysical inability to complete questionnaires\n4. Previous diagnosis or suspicion of another sleep disorder\n5. Presence of more than 50% of central apneas or Cheyne-Stokes respiration\n6. Having a serious chronic disease: neoplasia, renal failure, severe chronic obstructive pulmonary disease, chronic depression and other chronic limiting diseases\n7. Medical history that may interfere with the objectives of the study or, in the opinion of the researcher, may compromise the conclusions\n8. Any medical, social or geographical factor that may endanger the patient's compliance 9-Having a profession of high risk (professional driver).","100 Years",{"count":646,"type":20},64,[110],"The principal objective is to evaluate the effect of CPAP treatment on blood pressure (BP) in normotensive patients with dipper circadian pattern with sleep apnea-hypopnea syndrome (SAHS). The secondary objectives are: i) To evaluate the prevalence of the different circadian patterns of BP in ambulatory blood pressure monitoring (ABPM) ii) To establish the relationship between CPAP compliance and BP response; iii) Identify which ABPM variables and biomarkers are related to BP response; iv) Evaluate changes in the biomarkers' profile with the CPAP treatment. Methodology: Open-label, parallel, prospective, randomized and controlled trial including normotensive patients diagnosed with severe SAHS without significant somnolence. 64 patients with dipper circadian pattern will be included and will be randomized to receive CPAP (32) or conservative treatment (32). ABPM and blood sample collection will be performed at the beginning of the study and at 3 months.",[650,26],"Normotensive","2025-02-25",{"date":628,"type":35},{"date":654,"type":35},"2019-05-07",{"date":656,"type":20},"2025-12",{"name":658,"class":42},"Sociedad Española de Neumología y Cirugía Torácica"]